05.05.2017 • NewsDede WillamsXareltoBayer

J&J and Bayer Win First Xarelto Lawsuit

(c) Bayer AG
(c) Bayer AG

Bayer and Johnson & Johnson have won the first of around 18,000 lawsuits lawsuit being brought by US patients who claim the blood-thinning drug Xarelto caused their uncontrollable brain and gastrointestinal bleeding.

A federal jury in New Orleans, Louisiana found that the two companies, which developed Xarelto together and market it separately in Europe and the US, did not defectively design the drug nor mislead a Louisiana man and his doctors about the health risks.

Attorneys for the patients contend that J&J and Bayer should have warned patients that they could be tested to assess their bleed-out risk before taking the blood thinner, prescribed to prevent blood clots that can lead to fatal heart attacks and strokes, The drugmakers, however, said the New Orleans jury’s verdict finding affirms their product’s safety.

“The FDA-approved label contains accurate, science-based information on the benefits and risks of this life-saving medicine,” a J&J spokesperson told the news agency Bloomberg, while a US spokesperson for Bayer, said the New Orleans decision “reflects the facts of this case and the appropriateness of the Xarelto prescribing information.”

Three additional bellwether cases are expected to be heard over the next three months. Next up is a suit brought by the husband of a woman who used Xarelto for about a month before she died from a cerebral hemorrhage.

Xarelto is Bayer’s top-selling drug, with sales of around €3 billion ($3.24 billion) in 2016. It is J&J’s third-largest in terms of revenue, accounting for $2.29 billion last year. The blood thinner belongs to a new class of drugs designed to replace top-seller Coumadin, developed by a unit of US drugmaker Bristol Myers and on the market since the 1960s.

The difference between Xarelto and Coumadin, critics say, is that Xarelto has no antidote, so that some users are at high risk for bleeding out if they suffer an injury. Coumadin’s blood-thinning effects can be reversed, however.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

most read

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.